Delving into the Latest Updates on Shenzhen Maijiarui Biotechnology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Endocrinology and Metabolic Disease

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Endocrinology and Metabolic Disease	1
Infectious Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Bispecific antibody	2

Top 5 Target	Count

TGF-β1(Transforming growth factor beta 1)	1

主要目的：评估双特异性抗体MR001在晚期实体瘤患者中的安全性和耐受性；确定双特异性抗体MR001的剂量限制性毒性（DLT）和最大耐受剂量（MTD）。次要目的：评估双特异性抗体MR001在晚期实体瘤患者者中的药代动力学特征，获取初步药代动力学参数；评估双特异性抗体MR001在晚期实体瘤患者中的初步疗效，为后续临床试验推荐剂量提供依据；评价双特异性抗体MR001在晚期实体瘤患者中的免疫原性。探索性目的：探索双特异性抗体MR001在晚期实体瘤患者中的药效学指标的特征。

[Translation]

Primary objectives: To evaluate the safety and tolerability of the bispecific antibody MR001 in patients with advanced solid tumors; to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the bispecific antibody MR001. Secondary objectives: To evaluate the pharmacokinetic characteristics of the bispecific antibody MR001 in patients with advanced solid tumors and obtain preliminary pharmacokinetic parameters; to evaluate the preliminary efficacy of the bispecific antibody MR001 in patients with advanced solid tumors and provide a basis for the recommended dose for subsequent clinical trials; to evaluate the immunogenicity of the bispecific antibody MR001 in patients with advanced solid tumors. Exploratory objectives: To explore the characteristics of the pharmacodynamic indicators of the bispecific antibody MR001 in patients with advanced solid tumors.

Start Date28 Dec 2023

Sponsor / Collaborator

Shenzhen Maijiarui Biotechnology Co., Ltd.

100 Clinical Results associated with Shenzhen Maijiarui Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shenzhen Maijiarui Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Shenzhen Maijiarui Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shenzhen Maijiarui Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 1 Clinical

Login to view more data